BELLUS Health Inc BLUSD

Primary Symbol: T.BLU

Healthcare Biotechnology

BELLUS Health Inc. is a clinical-stage biopharmaceutical company developing therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. The Company's lead product candidate, BLU-5937, which is a selective, small molecule antagonist of the P2X3 receptor, as an oral therapy to reduce cough frequency in RCC patients. The Company has completed the BLUEPRINT clinical trial, a Phase II trial evaluating BLU-5937 in patients with chronic pruritus associated with AD. The Company is focused on initiating Phase III program. The Company is exploring the use of BLU-5937 in other patient populations experiencing cough hypersensitivity as well as other P2X3-related hypersensitization conditions.

TSX:BLU - Post by User

BELLUS Health Inc

Bullboard Posts

Comment by mbanxon Apr 25, 2011 7:03pm

405 Views

Post# 18485445

RE: 7 cents?

Quebec No. 2 (Broker Macquerie) got 20.6M shares on January 20th and another 34.2 M shares on February 7th.

Since January 7th, they have unloaded 12.7M shares under Macquerie broker, so we didn't see bottom yet as they now try to unload at .08, then .07, then .06 and so on...

Filing Date	Transaction Date	Insider Name	Ownership Type	Securities	Nature of transaction	# or value acquired or disposed of	Unit Price
Apr 22/11	Apr 22/11	Quebec No. 2 Holdings, LLC	Indirect Ownership	Common Shares	10 - Disposition in the public market	-999,999	.083
Apr 22/11	Apr 22/11	Quebec No. 2 Holdings, LLC	Indirect Ownership	Common Shares	10 - Disposition in the public market	-190,000	.081
Apr 12/11	Apr 07/11	Quebec No. 2 Holdings, LLC	Indirect Ownership	Common Shares	10 - Acquisition in the public market	34,242,911
Apr 12/11	Apr 07/11	Quebec No. 2 Holdings, LLC	Indirect Ownership	Common Shares	00 - Opening Balance-Initial SEDI Report
Feb 09/11	Feb 04/11	Quebec No. 2 Holdings, LLC	Direct Ownership	Common Shares	10 - Disposition in the public market	-2,009,998	.155